Patent US3758692A successfully refreshed from Google Patents.
US3758692A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Ylamines sympathomimetic process and compositions employing sulfonamidophenalk
Assignee: Mead Johnson and Co LLC
•
Filing: 1970-12-14
•
Granted: 1973-09-11
•
Expires: 1990-12-14
Abstract
Abstract Pharmaceutical compositions comprised of phenalkylamine compounds having both hydroxyl and sulfonamido groups in the phenyl ring are described. The sulfonamido-phenalkylamines are useful in decongestant and sympathomimetic processes.
Inventors
- 👤 A Larsen
- 👤 W Gould
- 👤 B Gould
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 03:35
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/16; A61K31/18; C; C07; C07C; C07C311/00; C07C311/01; C07C311/02
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
17 words
The process of claim 1 wherein 5''-(2-aminoethyl)-2''-hydroxymethanesulfonanilide or a pharmaceutically acceptable acid addition salt thereof is employed.
Claim 2
Dependent Claim
25 words
The decongestant process which comprises instilling into the nasal passages of a mammal an effective amount of a compound selected from the group consisting of
Claim 3
Dependent Claim
17 words
The process of claim 3 wherein 5''-(2-aminoethyl)-2''-hydroxymethanesulfonanilide or a pharmaceutically acceptable acid addition salt thereof is employed.
Claim 4
Dependent Claim
40 words
A liquid pharmaceutical composition suitable for parenteral or ophthalmic use, or application to the mucous membranes comprising a major proportion of a sterile liquid carrier and 0.1 to 10% by weight of a compound selected from the group consisting of
Claim 5
Dependent Claim
17 words
The composition of claim 5 wherein 5''-(2-aminoethyl)-2''-hydroxymethanesulfonanilide or a pharmaceutically acceptable acid addition salt thereof is employed.
Claim 6
Dependent Claim
34 words
A pharmaceutical composition in dosage unit form adapted for oral administration comprising a major proportion of a pharmaceutical carrier and from 5 to 50 mg. of a compound selected from the group consisting of
Claim 7
Dependent Claim
17 words
The composition of claim 7 wherein 5''-(2-aminoethyl)-2''-hydroxymethanesulfonanilide or a pharmaceutically acceptable acid addition salt thereof is employed.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1976-09-10 | 1977-03-12 | 1977-09-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1980-09-10 | 1981-03-12 | 1981-09-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1984-09-10 | 1985-03-12 | 1985-09-11 | $7700.00 | Window Closed / Lapsed |